The publication “A Self-Assembling Peptide with the Potential of Non-Invasive Regeneration of Early Caries Lesions” by Kind et al has won the IPJ-Prize 2015. The prize was awarded by the prize-committee and the presidency of the DGZMK (German Association of Dentistry).
The award winning report investigates the Mechanism of Action of the CUROLOX® Technology as it functions within the product Curodont™ Repair. The presented evidence therefore forms the basis for the newly proclaimed Guided Enamel Regeneration (GER) therapy.
“We feel honoured by the award as it shows that thorough, cutting edge science is the basis for the CUROLOX® Technology,” says Michael Hug, CTO of credentis and co-author of the award winning publication.
About Curodont™ and the Curolox® Technology
The patented CUROLOX® Technology is based on peptides self-assembling into a 3-dimensional matrix, triggering biomimetic mineralisation and repair. The core technology is the basis for all innovative credentis products.
CURODONT™ REPAIR provides dentists with a non-invasive option for natural in-depth mineralisation (GER) which allows the regeneration of caries lesions and similar defects. Applied to an early lesion, CURODONT™ REPAIR forms a scaffold within the lesion to guide new hydroxyapatite (tooth mineral) crystals to form and grow. Ideally, the caries is stopped and the lesion will mineralise within several weeks.
CURODONT™ PROTECT uses the CUROLOX® Technology to protect the tooth surface from acid attack. CURODONT™ D’SENZ is optimised for the treatment of dentine hypersensitivity, to be used before dental hygiene treatment or in conjunction with tooth bleaching.
With its regenerative product line, credentis supports the trend towards prevention and early treatment. The ultimate goal is to prevent caries through the use of its regenerative solutions and frequent recalls by dentists and hygienists.
About credentis ag
credentis ag is headquartered in the Technopark Aargau, Switzerland. credentis has won multiple awards as well as support from organizations such as Genilem. Public grants include Swiss National Science Foundation (SNF), Aargauer Forschungsfonds in collaboration with the FHNW School of Life Sciences in Muttenz and the Medical Technologies IKC (in co-operation with the University of Leeds).
Dr. Dominik Lysek, CEO and Michael Hug, CTO have a strong track record in science, development and medical technology, with focus in the dental industry. credentis board members Dr. Werner Berner, Dr. Michael Peetz, Gerard Moufflet and Dr. Erich Platzer (chairman), contribute their pharma, medtech and dental industry expertise.
Help employers find you! Check out all the jobs and post your resume.
